American Renal Associates Holdings Inc. (NYSE:ARA) was upgraded by Zacks Investment Research from a “sell” rating to a “hold” rating in a research note issued to investors on Monday.

According to Zacks, “American Renal Associates Holdings, Inc. is a provider of dialysis services primarily in the United States. It also offers outpatient and inpatient dialysis treatments for patients suffering from chronic kidney failure. American Renal Associates Holdings, Inc. is based in Beverly, Massachusetts. “

Other equities research analysts have also recently issued reports about the company. Leerink Swann reissued a “buy” rating on shares of American Renal Associates Holdings in a research report on Thursday, August 11th. SunTrust Banks Inc. set a $24.00 price objective on American Renal Associates Holdings and gave the company a “buy” rating in a research report on Thursday, October 13th. Bank of America Corp. reissued a “buy” rating and issued a $35.00 price objective on shares of American Renal Associates Holdings in a research report on Monday, August 22nd. Barclays PLC reduced their target price on American Renal Associates Holdings from $31.00 to $29.00 and set an “overweight” rating for the company in a research report on Friday, August 19th. Finally, Wells Fargo & Co. reaffirmed a “buy” rating on shares of American Renal Associates Holdings in a research report on Sunday, September 25th. Two investment analysts have rated the stock with a hold rating and five have issued a buy rating to the company. The company presently has a consensus rating of “Buy” and an average target price of $29.50.

Analyst Recommendations for American Renal Associates Holdings (NYSE:ARA)

American Renal Associates Holdings (NYSE:ARA) opened at 22.25 on Monday. The company’s market capitalization is $686.81 million. American Renal Associates Holdings has a 12 month low of $16.86 and a 12 month high of $29.65. The company has a 50-day moving average price of $18.11 and a 200 day moving average price of $23.37.

American Renal Associates Holdings (NYSE:ARA) last announced its quarterly earnings results on Thursday, November 10th. The company reported $0.28 EPS for the quarter, beating the consensus estimate of $0.24 by $0.04. American Renal Associates Holdings had a return on equity of 55.06% and a net margin of 1.92%. The company had revenue of $192.96 million for the quarter, compared to the consensus estimate of $189.73 million. The business’s revenue for the quarter was up 14.9% on a year-over-year basis. On average, equities research analysts forecast that American Renal Associates Holdings will post $0.96 EPS for the current fiscal year.

Several hedge funds have recently made changes to their positions in the stock. Centerbridge Partners L.P. acquired a new stake in shares of American Renal Associates Holdings during the second quarter worth $510,331,000. FMR LLC purchased a new stake in shares of American Renal Associates Holdings during the second quarter worth approximately $53,347,000. TimesSquare Capital Management LLC raised its stake in shares of American Renal Associates Holdings by 12.3% in the third quarter. TimesSquare Capital Management LLC now owns 1,190,450 shares of the company’s stock worth $21,750,000 after buying an additional 130,450 shares during the last quarter. Janus Capital Management LLC purchased a new stake in shares of American Renal Associates Holdings during the second quarter worth approximately $24,016,000. Finally, Vanguard Group Inc. purchased a new stake in shares of American Renal Associates Holdings during the second quarter worth approximately $17,327,000. Institutional investors own 84.13% of the company’s stock.

About American Renal Associates Holdings

American Renal Associates Holdings, Inc is a dialysis services provider in the United States. The Company focuses on joint venture partnerships with physicians. The Company’s segment is the ownership and operation of dialysis clinics. It provides patient care and clinical outcomes to patients suffering from the advanced stage of chronic kidney disease, known as end stage renal disease (ESRD).

5 Day Chart for NYSE:ARA

Receive News & Stock Ratings for American Renal Associates Holdings Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for American Renal Associates Holdings Inc. and related stocks with our FREE daily email newsletter.